AYTU BIOPHARMA, INC Quarterly Operating Income (Loss) in USD from Q4 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Aytu Biopharma, Inc quarterly/annual Operating Income (Loss) history and growth rate from Q4 2010 to Q2 2024.
  • Aytu Biopharma, Inc Operating Income (Loss) for the quarter ending June 30, 2024 was -$3.65M, a 2260% decline year-over-year.
  • Aytu Biopharma, Inc Operating Income (Loss) for the twelve months ending June 30, 2024 was -$5.25M, a 69.2% increase year-over-year.
  • Aytu Biopharma, Inc annual Operating Income (Loss) for 2024 was -$5.25M, a 69.2% increase from 2023.
  • Aytu Biopharma, Inc annual Operating Income (Loss) for 2023 was -$17.1M, a 84.5% increase from 2022.
  • Aytu Biopharma, Inc annual Operating Income (Loss) for 2022 was -$110M, a 86.7% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$5.25M -$3.65M -$3.82M -2260% Apr 1, 2024 Jun 30, 2024 10-K 2024-09-26
Q1 2024 -$1.44M -$2.46M +$6.09M +71.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$7.53M $2.36M +$9.23M Oct 1, 2023 Dec 31, 2023 10-Q 2024-02-14
Q3 2023 -$16.8M -$1.5M +$304K +16.8% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 -$17.1M $169K +$17.7M Apr 1, 2023 Jun 30, 2023 10-K 2024-09-26
Q1 2023 -$34.7M -$8.56M +$44.9M +84% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$79.6M -$6.87M +$4.43M +39.2% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-14
Q3 2022 -$84M -$1.81M +$25.9M +93.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$110M -$17.5M +$6.58M +27.3% Apr 1, 2022 Jun 30, 2022 10-K 2023-10-12
Q1 2022 -$116M -$53.4M -$27.8M -108% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$88.7M -$11.3M -$5.72M -103% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-21
Q3 2021 -$83M -$27.7M -$24.1M -679% Jul 1, 2021 Sep 30, 2021 10-Q/A 2023-02-21
Q2 2021 -$58.9M -$24.1M -$17.4M -263% Apr 1, 2021 Jun 30, 2021 10-K 2022-09-27
Q1 2021 -$41.4M -$25.7M -$20.9M -435% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$20.6M -$5.58M -$608K -12.2% Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-14
Q3 2020 -$20M -$3.56M +$1.18M +24.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$21.1M -$6.63M -$2.05M -44.9% Apr 1, 2020 Jun 30, 2020 10-K 2021-09-28
Q1 2020 -$19.1M -$4.79M -$495K -11.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q4 2019 -$18.6M -$4.97M -$416K -9.15% Oct 1, 2019 Dec 31, 2019 10-Q 2021-02-11
Q3 2019 -$18.2M -$4.74M -$1.32M -38.6% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$16.8M -$4.58M -$754K -19.7% Apr 1, 2019 Jun 30, 2019 10-K 2020-10-06
Q1 2019 -$16.1M -$4.3M +$3.23M +42.9% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q4 2018 -$19.3M -$4.55M -$557K -13.9% Oct 1, 2018 Dec 31, 2018 10-Q 2020-02-14
Q3 2018 -$18.8M -$3.42M +$939K +21.6% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$19.7M -$3.83M +$1.27M +25% Apr 1, 2018 Jun 30, 2018 10-K 2019-09-26
Q1 2018 -$21M -$7.52M -$2.66M -54.8% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-14
Q4 2017 -$18.3M -$3.99M +$205K +4.88% Oct 1, 2017 Dec 31, 2017 10-Q/A 2019-05-14
Q3 2017 -$18.5M -$4.36M +$1.61M +27% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 -$20.1M -$5.1M +$8.2M +61.7% Apr 1, 2017 Jun 30, 2017 10-K 2018-09-06
Q1 2017 -$28.3M -$4.86M -$1.63M -50.6% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-14
Q4 2016 -$26.7M -$4.2M -$1.18M -39.3% Oct 1, 2016 Dec 31, 2016 10-Q 2018-02-08
Q3 2016 -$25.5M -$5.97M -$3.8M -176% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 -$21.7M -$13.3M -$11.1M -518% Apr 1, 2016 Jun 30, 2016 10-K 2017-08-31
Q1 2016 -$10.6M -$3.23M -$1.42M -78.7% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-11
Q4 2015 -$9.13M -$3.01M -$1.43M -90.4% Oct 1, 2015 Dec 31, 2015 10-Q 2017-02-09
Q3 2015 -$7.7M -$2.16M -$71.4K -3.41% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-07
Q2 2015 -$7.63M -$2.15M -$2.14M -19226% Apr 1, 2015 Jun 30, 2015 10-K 2016-09-01
Q1 2015 -$5.49M -$1.81M -$1.79M -8685% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-11
Q4 2014 -$3.71M -$1.58M -$1.57M -10450% Oct 1, 2014 Dec 31, 2014 10-Q 2016-02-11
Q3 2014 -$2.14M -$2.09M -$2.08M -22956% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-06
Q2 2014 -$55.8K -$11.1K +$826 +6.91% Mar 1, 2014 May 31, 2014 10-Q 2014-07-10
Q1 2014 -$56.6K -$20.6K -$8.01K -63.8% Dec 1, 2013 Feb 28, 2014 10-Q 2015-04-15
Q4 2013 -$48.6K -$15K +$3.83K +20.3% Sep 1, 2013 Nov 30, 2013 10-Q 2015-01-12
Q3 2013 -$52.4K -$9.07K +$8.1K +47.2% Jun 1, 2013 Aug 31, 2013 10-K 2014-11-26
Q2 2013 -$60.5K -$12K -$873 -7.88% Mar 1, 2013 May 31, 2013 10-Q 2014-07-10
Q1 2013 -$59.6K -$12.6K -$3.33K -36.1% Dec 1, 2012 Feb 28, 2013 10-Q 2014-04-11
Q4 2012 -$56.3K -$18.8K +$43.00 +0.23% Sep 1, 2012 Nov 30, 2012 10-Q 2014-01-10
Q3 2012 -$56.4K -$17.2K +$53.6K +75.7% Jun 1, 2012 Aug 31, 2012 10-K 2014-11-26
Q2 2012 -$110K -$11.1K +$8.94K +44.6% Mar 1, 2012 May 31, 2012 10-Q 2012-06-26
Q1 2012 -$119K -$9.22K +$17.1K +64.9% Dec 1, 2011 Feb 29, 2012 10-Q 2012-04-12
Q4 2011 -$136K -$18.9K -$2.33K -14% Sep 1, 2011 Nov 30, 2011 10-Q 2013-01-14
Q3 2011 -$134K -$70.7K Jun 1, 2011 Aug 31, 2011 10-K 2012-11-29
Q2 2011 -$20K Mar 1, 2011 May 31, 2011 10-Q 2012-06-26
Q1 2011 -$26.3K Dec 1, 2010 Feb 28, 2011 10-Q 2012-04-12
Q4 2010 -$16.6K Sep 1, 2010 Nov 30, 2010 10-Q 2011-12-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.